Rad51 is a protein which has been studied in canine tumors due to its connection with BRCA2, and several studies have documented Rad51 mutations in tumor canine cells (75–77)Bortezomib, a proteasome inhibitor that impairs HR and thus decreases the expression of Rad51, has been used to potentiate the effect of other drugs, such as inhibitors of poly (ADP-ribose) polymerase (iPARP) or MEDI2228. Here, RAD51 is linked to neoplasm.